‘Surge' in COVID-19 Cases in India: What We Know and Don't Know About Newer Strains
Menu
हिंदी తెలుగు اردو
Home Politics Economy World Security Law Science Society Culture Editor's Pick Opinion
Support independent journalism. Donate Now
Top Stories
'Surge' in COVID-19 Cases in India: What We Know and Don't Know About Newer Strains
Banjot Kaur
42 minutes ago
Current data is inadequate to draw a complete picture. Hyperbolic news coverage also hides key scientific details of the situation.
A medic at a ward prepared for COVID-19 patients at Gandhi Hospital in the wake of several states reporting Covid cases, in Hyderabad, Saturday, May 24, 2025. Photo: PTI.
Real journalism holds power accountable
Since 2015, The Wire has done just that.
But we can continue only with your support.
Contribute now
New Delhi: The 'surge' in COVID-19 cases has been making headlines in India for about a week now. What should one make of the term 'surge'? Is the rise in the number of cases cause for alarm?
The prevailing notion that 'COVID-19 is back' does not pass scientific muster because like any other virus, Sars-Cov-2 (causing COVID-19), never went away. Like all other viruses, it has been circulating all this time and will continue to do so. No virus has been eliminated in human history except smallpox.
The periodic rise in cases is also likely to happen because Sars-Cov-2 is a fast-mutating virus. These are the 'surges' that are leading to a misinformed claim that 'COVID-19 is back'.
Current 'surge'
According to the data made available by the Union health ministry's online dashboard, there are 1,010 active cases in India as of May 25. The highest number of active cases are in Kerala (430) followed by Maharashtra (210), Delhi (104) and Gujarat (76).
One of the metrics to understand the numbers is to look at the baseline which reflect the weekly change in the number of cases. Compared with week starting May 19, the highest change in the number of cases has been in Kerala (95 cases more cases this week) and Maharashtra (56 more cases this week),
In such a situation, governments can make additional preparations and ask hospitals to remain at stand by as a standard protocol.
Why this data is not the real picture
The official data has several riders which are often missed in the current discourse and in panicked messages widely circulated on various social media platforms. The most important among them is the positivity rate, i.e, number of tests returning positive out of every 100 tests conducted. This is important to rule out any testing bias.
Usually, when talk around COVID-19 cases going up gains momentum, a higher number of people get tested for the virus. The higher the number of people being tested, the greater are our chances of detecting more cases. This is the case because in the absence of such talk, fewer people get tested, and therefore, the number of people being tested positive is also small. Therefore, it is pertinent to know the positivity rate.
The health ministry website has no updated information on the positivity rate of the current strains.
The fact that Kerala has the highest number of positive cases can, therefore, also be a function of more tests being conducted there.
Virus surveillance
The Indian SARS-CoV-2 Genomics Consortium (INSACOG) is responsible for conducting genomic surveillance and finding out the current status of the strains circulating. Some of the tests that return positive are further analysed to understand the most commonly circulating strain. According to the INSACOG dashboard updated till May 26, JN.1 is the most common circulating strain.
Some cases of a new strain NB.1.8.1 have also been reported but are not reflected in the dashboard.
However, the number of sequences uploaded on the INSACOG dashboard has been extremely low, starting this year, thus seriously limiting the Indian genome sequencing capacity and its surveillance efforts. It is through genome sequencing alone that one can understand the scale of the dominant strain at a given point in time.
In fact, only five centres out of 64 have uploaded the results of sequencing that started in January this year. Two medical colleges of Rajasthan and Gujarat, each, and the country's apex body, the National Institute of Virology, have done so. Therefore, less-than-adequate genome sequencing can also present a picture which is incomplete.
Even the last INSACOG bulletin, issued on May 15, acknowledges this. 'Since the testing and the sampling frequency is less for some parts of India, the overall scenario might not be clear yet,' it says.
Many countries do wastewater surveillance also to study the true prevalence of any strain as it reveals viral load or fragments of virus in sewage.
In India, only a few entities do this in their own capacities. There is no centralised data available on this as the Union government has not taken up wastewater surveillance, even at the start and peak of the pandemic.
WHO's classification of JN.1 and NB.1.8.1
The World Health Organisation (WHO) classifies new emerging strains under one of the three categories – variants under monitoring (VUM), variants of Interest (VoIs) and variants of Concern (VoCs). The least alarming are the ones classified as VuMs. If a strain is designated as VuM, it is a 'signal to health authorities that a new strain may require prioritised attention' over others.
If a strain is classified as VoI, it indicates that it has the ability to spread faster than the previous cousins, cause a slightly more severe disease and 'suggests a potential emerging risk to global public health'.
The strains classified as VoCs signal the highest degree of change. Such a strain may potentially overwhelm health systems across the world. A VoC can cause 'detrimental' change in disease severity, and cause significant immune evasion, that is, the circulating strain is successful in evading the immune system.
Currently, the WHO has classified JN.1 as VoI. NB.1.8.1 has been characterised as VuM.
All currently circulating strains are offshoots of the Omicron variant.
Properties of NB.1.8.1 and JN.1
NB.1.8.1 has a greater ability than its previous cousins to bind to ACE2 receptors. The ACE2 receptors are present in cells of various body parts and they act as entry points for the COVID-19 virus into the body. The COVID-19 virus has what are known as 'spike proteins', or simply, spikes present on its outer surface. These spikes of the virus 'bind' with ACE2 receptors like lock and key to invade the body.
Thus, the fact that NB.1.8.1 has a greater ability to bind with ACE2 receptors of the body indicates that it can easily gain entry into the body. This can increase the transmission potential of the virus – it can thus spread faster from one person to another.
According to the latest WHO update, limited available evidence from different parts of the world indicates that this strain has led to an increase in hospitalisation numbers.
However, these are early days for full evaluation of the NB.1.8.1. This is the case because the COVID-19 sequences global database, GISAID, has only 518 samples of this strain provided by 22 countries. This number is not enough to study its clinical outcomes in detail.
'The routine clinical surveillance data do not indicate any signs of increased severity associated with NB.1.8.1, compared to previously circulating strains,' says the WHO in its latest update.
'Currently there is no evidence of increases in indicators like COVID-19-related ICU admissions and deaths per hospitalisations, or all-cause mortality,' it adds.
As far as JN.1 is concerned, which is currently the dominant strain in India, it has a growth advantage over previously circulating strains, as per the WHO. In other words, it can spread faster than other Omicron strains.
However, the neutralisation capacity of the antibodies present in the immune system, i.e., their ability to neutralise or kill the virus is same for JN.1 as it is for other strains of the Omicron variant which had been circulating earlier.
The WHO says the currently available evidence suggests that the additional health risk posed by JN.1 is low at the global level. The increase in hospitalisation numbers with JN.1 is unclear at the moment.
There have been no reports of changes in disease severity with JN.1 as compared to other versions of the Omicron variant.
According to this paper, JN.1 can cause fever, sore throat, excessive discharge of mucus from nose, nasal congestion, persistent dry cough, fatigue, headache, loss of taste, loss of smell, muscle pain, conjunctivitis, diarrhoea, and vomiting.
'Patients infected with the JN.1 strain may experience more severe muscle fatigue and exhaustion compared to typical COVID-19 cases,' it says.
'Mild symptoms can often be managed with symptomatic care and do not require immediate medical attention,' it adds.
Patients who are immunocompromised – those whose immune systems are already compromised – due to certain illnesses are always at risk of developing a severe disease than others, be it any strain of the virus.
Another risk associated with any variant of Sars-Cov-2 infection is Long COVID. While all the currently circulating strains are mostly known to cause a mild version of the disease, the risk of Long COVID is real and pertinent.
WHO's technical lead on COVID-19, Maria Van Kerkhove, says, there is no substantial clarity as to how COVID-19 infections can impact our body in multiple ways even if one has got rid of the infection. 'Our concern is [that] in five years from now, 10 years from now, 20 years from now, what we are going to see in terms of cardiac impairment, of pulmonary impairment, of neurological impairment [caused due to long term impacts of new strains of the virus which would continue to emerge],' she says referring to Long COVID.
§
Although the fear of the 'unknowns' of this virus has subsided to a greater extent, not everything is known about the virus yet, as Kerkhove says.
The best and the easiest way is, therefore, to take precautions which are not hard to follow. Vulnerable populations like elderly, people with comorbidities and compromised immune systems, especially need to take care. Insofar as the general population, following these precautions, like masking up in crowded places, can alway come handy to dodge the virus and its long term implications.
Make a contribution to Independent Journalism
Related News
The Small Peak in COVID-19 Cases in South East Asia Is No Cause For Panic
COVID-19 Led to Decline in Life Expectancy in India, Reveal Three Analyses
The Many Failures of Operation Sindoor
We Must Assess Sudden Deaths Which Took Place as a Consequence of COVID-19
Undercounting of COVID Deaths: Two Million More People Died in 2021 Compared to 2020, Shows Govt Data
ECI Tried to Address the Duplicate EPIC Problem 4 Years Ago. Why Does it Persist?
Free Speech on Eggshells: What the Ali Khan Mahmudabad Case Signals for All of Us
Global Leaders Have Much to Learn From Singapore PM Lawrence Wong's Speech on US Tariffs
Former Election Commissioner Ashok Lavasa Says EC Must Explain 'Abnormal Surge' in Electors: Report
About Us
Contact Us
Support Us
© Copyright. All Rights Reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
No 2020-Like Repeat Of Covid-19, Influenza A Bigger Risk: Ex-WHO Scientist Soumya Swaminathan
Last Updated: Addressing fears of another catastrophic wave, Swaminathan said periodic surges—roughly every 6-8 months—are expected, largely manageable, and low in severity Influenza, and not Covid-19, likely claims more lives each year in India and globally despite the latter dominating headlines, Dr Soumya Swaminathan, former chief scientist at the World Health Organization (WHO), has told News18. One of the leading experts on infectious diseases, Swaminathan has reassured the public that there is 'absolutely no need to panic now". In an exclusive interview, Swaminathan told News18 that the SARS coronavirus, much like influenza, is now part of the respiratory viruses regularly circulating in the population. ' COVID or SARS-CoV-2, which is the virus, is another respiratory virus, like the many others that are circulating amongst us human beings in the world today. It has been around for five years now. It's, of course, constantly mutating and changing, like other viruses," she said. When asked whether there's a possibility of another 'Delta-like' wave making a return, she said the public needs to understand 'very clearly" that 'we will not see the repeat of 2020 or 2021. At that time, human beings had never seen this virus before". According to her, these periodic surges—roughly every 6-8 months—are expected and largely manageable. 'We have also now started seeing that periodically…There is a rise in circulating Covid-19 cases," she noted, citing data from the Indian Council of Medical Research (ICMR), which indicates that the Omicron variant JN.1 has recently become the dominant strain. Swaminathan, before her ground-breaking role at WHO, was the Director General of the Indian Council of Medical Research (ICMR) and secretary of the Department of Health Research in India. She, however, says that despite the increase in cases, the severity remains low. 'What you're seeing now is a mild disease mostly. Even though people are testing and reporting positivity, you find that hospitalisations are rare," she said. Swaminathan highlighted that individuals with underlying health conditions should continue to take precautions. 'People who have underlying illnesses… are likely to get a little sicker when they get a respiratory infection," she warned, adding that this applies to both Covid-19 and influenza. The flu virus may pose a greater threat than Covid-19. 'Influenza probably kills a lot more people in India and around the world… it makes a lot of sense for vulnerable people to take the flu vaccine, which gets updated every year." Addressing fears of another catastrophic wave, she assured the public: 'It will not happen that we will have a repeat of 2020 or 2021… Today, the virus cannot spread in the same way because it is met with a strong immune response." Do we need booster shots or updated vaccines? According to Swaminathan, there is a need to evaluate the efficacy and cost-effectiveness of updating vaccines, especially in countries like India. 'We see that illness is mild, not requiring hospitalisation… There doesn't seem to be any reason to start a booster campaign now," she said, although she acknowledged the importance of preparing for potential future variants through continued research and updated vaccine development. She also outlined five key areas for pandemic preparedness. 'We need new legislation today that will cover biological threats like pandemics," she said, adding that 'India should have its own list of priority pathogens… and mechanisms for developing vaccines and therapeutics". Also, she said: 'Every state must have a public health cadre… It's essential to deal with so many health risks today, along with the improvement of health literacy and public engagement, which is critical." What should you do? 'Let's take sensible precautions… I see people travelling in crowded buses, trains, and planes, coughing and sneezing without a mask—that's just spreading infection." As for concerns about waning immunity, she explained, 'There are two kinds of immunity… antibodies, which decline over time, and T-cells, which have memory. The moment you are exposed again to the same virus… your immune system does its job." She emphasised that Covid-19 is now an endemic part of life. While vigilance and preparedness are necessary, panic is not. 'We can rest assured now… I would say, let's take sensible precautions… but there's no need for any panic." Watch India Pakistan Breaking News on CNN-News18. Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! First Published:
India Gazette
an hour ago
- India Gazette
India's health insurance sector faces growth and profitability challenges: Report
New Delhi [India], June 2 (ANI): India's health insurance industry, which was earlier considered a strong and steady growth story, is now facing serious structural challenges. A recent report by Elara Capital has highlighted that both growth and profitability in the sector are being affected, which may redefine the long-term potential of health insurers in the country. It said, 'India's health insurance industry, long seen as a secular growth story, is facing structural constraints in terms of growth as well as profitability'. According to the report, one of the key reasons behind this slowdown is the overestimation of the total addressable market (TAM) for private insurers. Many experts had earlier projected a large market for private health insurance. However, with the expansion of government-sponsored health schemes that offer widespread coverage, the actual market available for private players has reduced. This has made it more difficult for private insurers to grow at the pace previously expected. At the same time, increasing competition in the sector is adding more pressure. The report noted that factors such as a shift in policy mix toward older or vintage policies and the growing bargaining power of hospitals and insurance distributors are affecting the profitability of health insurance companies. These trends are putting a cap on the margins of insurance manufacturers. The report also pointed to the entry of LIC into the health insurance segment, along with other life insurance companies that are expected to enter through composite licenses. This will further intensify competition and could limit growth opportunities for traditional standalone health insurers (SAHI). Due to these challenges, the report advised investors to lower their long-term expectations for broad-based growth in the health insurance sector. Instead, they should focus on more resilient areas such as third-party administrators (TPAs) and diversified multi-line private general insurers, which tend to have stronger business models and better profitability. Another concern is the rising cost of claims. The report explained that after COVID-19, there has been a shift in focus toward critical illnesses like cancer and heart conditions. This has led to higher claim frequency and severity, putting additional pressure on insurers. Loss ratios remain high, and the situation is worsened by increasing hospital occupancy, which has gone up from 52 per cent in FY21 to 64 per cent in FY25. Along with this, the average revenue per occupied bed (ARPOB) has grown at a compound annual growth rate (CAGR) of around 10 per cent, further driving up the cost of claims. In summary, the report highlighted that India's health insurance sector is going through a structural change. While traditional players may face limited growth, new opportunities exist in niche segments with better economics. (ANI)
News18
an hour ago
- News18
Active Covid-19 Cases In India Surge To 3,758; West Bengal Reports Maximum In 24 Hours
Last Updated: India reported 363 new Covid-19 cases on June 1, with active cases rising to 3,758 and two new deaths recorded. Kerala has the highest number of active cases. India on Sunday (June 1) reported 363 new cases of the Covid-19, taking the total active cases in the country to 3,758, the Ministry of Health and Family Welfare stated on Monday. According to the data, West Bengal reported 82 new cases – the maximum among all states, followed by Kerala, which reported 64, and Delhi, which reported 61 new cases of the coronavirus in the past 24 hours. However, at 1400, Kerala presently has the highest number of total active cases. The total active cases in Maharashtra were 485, while Delhi reported 436 total active cases. The total number of active cases in Gujarat stood at 320, while 287 was the total in West Bengal. Karnataka and Kerala reported one death each in the past 24 hours. Since January 1, 2025, Kerala and Maharashtra reported seven deaths each due to Covid-19. Four deaths were reported from Karnataka, and three from Delhi. The country has reported 28 deaths so far this year due to the coronavirus. Meanwhile, a total of 383 Covid-19 patients recovered from the infection in the past 24 hours. On May 29, a 63-year-old man with co-morbidities and who tested positive for Covid-19 died at a private hospital in Bengaluru. He was admitted to a private hospital in Bengaluru Urban (Bruhat Bengaluru Mahanagara Palike limits) on May 21 after he complained of weakness and died a week later. According to the health department statement, the elderly patient who was fully vaccinated was on post-operative chemotherapy and had co-morbidities like pulmonary TB with squamous cell carcinoma of the buccal mucosa. Earlier, a 60-year-old woman who was suffering from acute intestinal obstruction died of Covid-19 in Delhi. Last week, Delhi Chief Minister Rekha Gupta said 19 Covid patients were hospitalised in Delhi, but there was no need to worry. The Delhi government is alert and hospitals are ready, the Chief Minister told reporters at Lok Nayak Jai Prakash Hospital in the national capital. 'Nineteen patients are admitted to hospitals and the remaining are receiving treatment at their homes. But Covid-19 has not reached the point where people need to worry. The government is ready for every situation," Gupta said. She also underlined the need for people to remain cautious. Last week, the Delhi government issued an advisory to hospitals, asking them to ensure availability of beds, medicines and oxygen. First Published: June 02, 2025, 09:52 IST
